Web3 apr. 2024 · In few cases, statins have been reported to induce de novo or aggravate pre-existing myasthenia gravis or ocular myasthenia (see section 4.8). Pravastatin should be discontinued in case of aggravation of symptoms. Recurrences when the same or a different statin was (re-) administered have been reported. Interstitial lung disease Web24 aug. 2024 · Simply put, brand-name Lipitor and generic atorvastatin are the same medication, and, because of that, each is just as safe and effective as the other. Lipitor is made by Pfizer and generic Lipitor, which was first available in November 2011, is made by many different companies. The efficacy of generic drugs has also been tested in studies.
Pravastatin vs. Lipitor: Differences, similarities, and which is better ...
Webpotency statins reduce CVD more than lower doses or lower potency statins.5 Therefore, recommended dosing should be based on intensity (representing both potency in the type of statin and dose) of statin therapy (see Table 2). Intensity Statin Options Low Intensity Pravastatin 10-20mg; Lovastatin 10-20mg; Simvastatin 5-10mg; http://www.mqic.org/pdf/UMHS_Statin_Dose_Intensity_and_Equivalency_Chart.pdf candy van alen newport ri
Cost-effectiveness analysis of high, intermediate, and low dose statins …
WebCONCLUSIONS We conclude that the treatment effect of 40 mg/d of pravastatin is proportionally the same regardless of baseline lipid ... neutral, or, as is especially the case with HMG-CoA reductase inhibitors (statins), beneficial. Pleiotropic effects of statins include improvement of endothelial dysfunction, increased nitric oxide ... WebBackground and Objectives: The efficacy of hydroxy methyl glutaryl-coenzyme A reductase inhibitors (statins) in reducing the incidence of cardiovascular events pushed the target LDL-cholesterol (LDL-C) levels lower and lower in successive guidelines despite signals regarding potential cognitive side effects. We evaluated the relationship between … WebCan cause elevations in hepatic transaminases; in a clinical trial, 10 (34%) of the 29 patients treated with lomitapide had at least 1 elevation in ALT or AST ≥3x ULN. Also increases hepatic fat (median increase 6%), with or without concomitant increases in transaminases, which may lead to progressive liver disease. candy vargas